drug
thiotepa
Marketedupdated 3mo agoby STI Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying thiotepa
- phase2Itacitinib for the Prevention of Graft Versus Host Disease
- phase1Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
- phase2Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
- phase2Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
- phase2Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 31, 2037
~10.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 16, 2041formulationUS 11975013
- Aug 16, 2041formulationUS 11975013
- May 31, 2037formulationUS 9931458
- May 31, 2037formulationUS 9931458
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 43m ago
Found something off?
comments(0)
5-min edit window · permanent after that